Genprex was founded by John Rodney Varner, Rodney Varner.

How much funding has Genprex raised?

Genprex has disclosed $11.1M raised across 3 of its 8 known rounds.

Where is Genprex headquartered?

Genprex is headquartered in Austin, US.

Genprex

NASDAQ: GNPX

Austin, US · Texas corporation

Find your way into Genprex

Paths you didn't know you had: your email and LinkedIn already hold routes to the Genprex team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes, including approaches that reintroduce tumor suppressor genes and stabilize glucose levels. Its therapies have received multiple FDA Fast Track Designations and are being evaluated in clinical trials.

Biotech Healthtech

Founders & leadership

John Rodney VarnerCo-founder

Rodney Varner FounderRodney Varner is co-founder, Chairman, and CEO of Genprex (Nasdaq: GNPX), a clinical-stage gene therapy company developing treatments for cancer and diabetes.

Ryan M. Confer President, Chief Executive Officer, & DirectorRyan Confer serves as President, Chief Executive Officer, and Chief Financial Officer of Genprex, a clinical-stage gene therapy company. His career has focused on identifying emerging technologies in academic and laboratory settings and translating them into commercial applications, with experience investing in and developing companies across SaaS, medical devices, fintech, and industrial design.

Mark S. Berger Chief Medical OfficerMark S. Berger is Chief Medical Officer at Genprex, a gene therapy company developing treatments for cancer and diabetes. He has over 25 years of experience in oncology drug development across large pharmaceutical and biotech companies, including leadership roles at GlaxoSmithKline, Wyeth Research, Deciphera Pharmaceuticals, Kadmon, and Actinium Pharmaceuticals, where he contributed to the development and approval of multiple therapeutics including Tykerb and Mylotarg.

Board

Bob PearsonBoard director

David FriedmanBoard director

Reported raises · per SEC filings

Form D private placements

$11.1M disclosed across 3 of 8 rounds · 1900–2019

▶$1.5MofferedNov 2019 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Robert W. PearsonDirector
David E. FriedmanDirector
Julien PhamExecutive Officer
Ryan M. ConferExecutive Officer
John Rodney VarnerExecutive Officer, Director

Offering amount: $1.5M
Sales commissions: $88.7K
Placement agents: Joseph Gunnar & Co., LLC
First sale: Nov 2019
Incorporated: Corporation, Texas
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedMay 2018 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Julien PhamExecutive Officer
John Rodney VarnerExecutive Officer, Director
David FriedmanDirector
Robert PearsonDirector
Ryan ConferExecutive Officer

Offering amount: $10M
Amount sold: $10M
Sales commissions: $700K
Placement agents: Maxim Group LLC
First sale: May 2018
Incorporated: Corporation, Texas
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$950KraisedOct 2016 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ryan ConferExecutive Officer
David FriedmanDirector
John Rodney VarnerExecutive Officer, Director
Bob PearsonDirector

Amount sold: $950K
Minimum investment: $25K
Sales commissions: $47.2K
Placement agents: Network 1 Financial Securities, Inc.
First sale: Sep 2016
Incorporated: Corporation, Delaware
Federal exemptions: 05, 06b, 4a5

Full filing on SEC EDGAR ↗

▶$160KraisedMar 2015 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Bob PearsonDirector
David FriedmanDirector
John Rodney VarnerExecutive Officer, Director

Offering amount: $1.5M
Amount sold: $160K
Minimum investment: $20K
First sale: Feb 2015
Incorporated: Corporation, Delaware
Federal exemptions: 05, 06b, 4a5

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$75.9Mvaluation at IPOOct 2017 · $5.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 6

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.

PerplexityAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.

QuiverquantQuiver Quantitative scrapes and aggregates alternative stock market data from across the internet into a free web dashboard. It targets retail investors, giving non-professional traders access to alternative data typically reserved for institutional money managers.

Companies working in the same space as Genprex.

In the news

Genprex posts Q2 2026 results and cash runway update | GNPX Quarterly Report (10-Q)stocktitan.net · Aug 2026

Frequently asked questions

What does Genprex do?: Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes, including approaches that reintroduce tumor suppressor genes and stabilize glucose levels. Its therapies have received multiple FDA Fast Track Designations and are being evaluated in clinical trials.
Who founded Genprex?: Genprex was founded by John Rodney Varner, Rodney Varner.
How much funding has Genprex raised?: Genprex has disclosed $11.1M raised across 3 of its 8 known rounds.
Where is Genprex headquartered?: Genprex is headquartered in Austin, US.